Evidence map›Paper›PMID 29707611›Full record

ArticleNeurology(R) neuroimmunology & neuroinflammation2018

Monitoring B-cell repopulation after depletion therapy in neurologic patients.

Erik Ellwardt, Lea Ellwardt, Stefan Bittner, Frauke Zipp

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology(R) neuroimmunology & neuroinflammation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 77 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Assessing Sustained B-Cell Depletion and Disease Activity in a French Multiple Sclerosis Cohort Treated by Long-Term IV Anti-CD20 Antibody Therapy.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023
    Article
  10. Article
  11. Observational
  12. Treatment and Relapse Prevention of Typical and Atypical Optic Neuritis.International journal of molecular sciences · 2022
    Review
  13. Observational
  14. Article
  15. Review
  16. Article
  17. A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20-Yet Progress Continues.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021
    Review
  18. Influence of immunomodulatory drugs on the gut microbiota.Translational research : the journal of laboratory and clinical medicine · 2021
    Review
  19. Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021
    Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

Erik EllwardtFocus Program Translational Neurosciences (FTN) and Immunology (FZI) (E.E., S.B., F.Z.), Rhine Main Neuroscience Network (rmn), Department of Neurology, University Medical Center of the Johannes Gutenberg University Mainz; and Institute of Sociology and Social Psychology (L.E.), University of Cologne, Germany.
Lea EllwardtFocus Program Translational Neurosciences (FTN) and Immunology (FZI) (E.E., S.B., F.Z.), Rhine Main Neuroscience Network (rmn), Department of Neurology, University Medical Center of the Johannes Gutenberg University Mainz; and Institute of Sociology and Social Psychology (L.E.), University of Cologne, Germany.
Stefan BittnerFocus Program Translational Neurosciences (FTN) and Immunology (FZI) (E.E., S.B., F.Z.), Rhine Main Neuroscience Network (rmn), Department of Neurology, University Medical Center of the Johannes Gutenberg University Mainz; and Institute of Sociology and Social Psychology (L.E.), University of Cologne, Germany.
Frauke ZippFocus Program Translational Neurosciences (FTN) and Immunology (FZI) (E.E., S.B., F.Z.), Rhine Main Neuroscience Network (rmn), Department of Neurology, University Medical Center of the Johannes Gutenberg University Mainz; and Institute of Sociology and Social Psychology (L.E.), University of Cologne, Germany.
Johannes Gutenberg University Mainz · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo determine the factors that influence B-cell repopulation after B-cell depletion therapy in neurologic patients and derive recommendations for monitoring and dosing of patients.

methodsIn this study, we determined the association of body surface area (BSA; calculated by body weight and height with the Dubois formula), sex, pretreatment therapy, age, CSF data, and white blood cell counts with the risk and timing of B-cell repopulation, defined as 1% CD19

resultsPatients with a larger BSA had a higher probability to reach 1% CD19

conclusionsB-cell repopulation after depletion therapy displays both high inter- and intra-individual variance. Our data indicate that a larger BSA is associated with faster repopulation of B cells, even when treatment is adapted to the BSA. A reason is the routinely used Dubois formula, underestimating a large BSA. In these patients, there is a need for a higher therapy dose. Because B-cell count-dependent therapy regimes are considered to reduce adverse events, B-cell monitoring will stay highly relevant. Patients' BSA should thus be determined using the Mosteller formula, and close monitoring should be done to avoid resurgent B cells and disease activity.

Identifiers

PMID29707611
PMCPMC5919296
OpenAlexW2802650011

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.